Dificid Approved to Treat C. diff Diarrhea

Recommended dosage is two times daily for 10 days

TUESDAY, May 31 (HealthDay News) -- Dificid (fidaxomicin) has been approved by the U.S. Food and Drug Administration to treat diarrhea associated with Clostridium difficile infection.

Dificid was evaluated in clinical studies involving 564 people with C. diff-associated diarrhea. More people who took Dificid were still symptom-free three weeks after stopping treatment than those who took vancomycin, the FDA said.

Recommended dosage with Dificid is twice daily for 10 days. The most common side effects reported included nausea, vomiting, headache, abdominal pain, and diarrhea.

Dificid was developed by Optimer Pharmaceuticals, based in San Diego.

More information

To learn more about this illness, visit the U.S. Centers for Disease Control and Prevention.

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events